Arturo LoAIza-Bonilla: Honored to serve as Chair of the AI-Driven Precision Medicine session at TriCon
Arturo LoAIza-Bonilla, Associate Professor of Medicine at the Lewis Katz School of Medicine at Temple University, shared a post on LinkedIn:
“I was honored to serve as Chair of the “AI-Driven Precision Medicine: Harnessing Biomarkers, Data, and Drug Discovery to Advance Oncology” session at TriCon. As both Co-Founder of Massive Bio and Network Chief of Hematology and Oncology at St. Luke’s University Health Network, I’m passionate about how artificial intelligence can truly transform cancer care.
I was joined by an outstanding panel of experts:
• Heather Jorajuria (Foundation Medicine) who shared how AI is enhancing genomic profiling to pinpoint actionable biomarkers more quickly.
• Bahar Rahsepar, (PathAI) who highlighted how AI in digital pathology is pushing the boundaries of diagnostic precision and clinical decision-making.
• Crystal Stephens, (Regeneron), who discussed how AI is accelerating targeted oncology drug discovery and development.
We explored real-world examples of AI’s impact—from improving patient stratification in clinical trials to enabling ‘just in time’ activation of studies. At Massive Bio, we’re thrilled to integrate these AI-driven insights into innovative clinical trial matching programs, including the recent ACS ACTS initiative, which aims to make trials more accessible and equitable for patients everywhere.
St. Luke’s University Health Network has been a phenomenal partner in this mission, and I’m proud to lead our Cancer Service Line in an environment that values collaboration and innovation. Whether it’s implementing advanced genomic tools from Foundation Medicine, leveraging digital pathology breakthroughs from PathAI, or learning from Regeneron’s AI-driven biomarker discovery, one thing is certain: working together across health systems, pharma, and technology is key to driving real change in oncology.
The future of precision oncology will be powered by interdisciplinary teamwork, actionable data insights, and a commitment to equitable patient care. I’m excited to continue partnering with industry leaders to ensure we harness AI’s full potential in cancer diagnosis, treatment, and clinical research, and pre-screening hubs. Here’s to the ongoing collaboration that will shape the next generation of precision medicine!”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023